<DOC>
	<DOCNO>NCT01763866</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week evolocumab administer subcutaneously every 2 week ( Q2W ) monthly ( QM ) use combination statin , compare placebo , percent change baseline low-density lipoprotein cholesterol ( LDL-C ) patient primary hypercholesterolemia mixed dyslipidemia .</brief_summary>
	<brief_title>LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2</brief_title>
	<detailed_description>Prior first randomization , participant enter screening period determine eligibility . During screen , participant receive subcutaneous placebo correspond monthly dose volume . Participants complete screening period meet eligibility criterion randomize 1 5 open-label statin cohort ( atorvastatin 10 mg 80 mg , rosuvastatin 5 mg 40 mg , simvastatin 40 mg ) 4 week lipid stabilization period base statin therapy time study entry ( statin use vs non-intensive statin use v intensive statin use ) . After 4-week lipid-stabilization period , eligible patient take rosuvastatin simvastatin lipid-stabilization phase randomize 1 4 treatment group : evolocumab ( 140 mg , subcutaneous , every 2 week ) match placebo ( subcutaneous , every 2 week ) , evolocumab ( 420 mg , subcutaneous , monthly ) match placebo ( subcutaneous , monthly ) . Patients take atorvastatin lipid-stabilization phase randomize 1 6 treatment group : evolocumab ( 140 mg , subcutaneous , every 2 week ) placebo ( oral , daily ) , evolocumab ( 420 mg , subcutaneous , monthly ) placebo ( oral , daily ) , placebo ( subcutaneous , every 2 week ) placebo ( oral , daily ) ezetimibe ( 10 mg , oral , daily ) , placebo ( subcutaneous , monthly ) placebo ( oral , daily ) ezetimibe ( 10 mg , oral , daily ) . A participant consider randomize study successfully complete screen period , meet inclusion/exclusion criterion , undergo randomization procedure . Participants randomize simvastatin take verapamil diltiazem prior randomization receive simvastatin 10 mg daily ( QD ) participant take amlodipine , amiodarone ranolazine prior randomization receive simvastatin 20 mg QD . All participant randomize simvastatin receive simvastatin 40 mg QD .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female ≥ 18 ≤ 80 year age Subjects take statin must fast LDLC least 150 mg/dL ( 4.0 mmol/L ) Subjects already nonintensive statin must fast LDLC screen ≥ 100 mg/dL ( 2.6 mmol/L ) Subjects already intensive statin must fast LDLC screen ≥ 80 mg/dL ( 2.1 mmol/L ) Fasting triglyceride ≤ 400 mg/dL ( 4.5 mmol/L ) Statin intolerance New York Heart association ( NYHA ) III IV heart failure Uncontrolled hypertension Uncontrolled cardiac arrhythmia Type 1 diabetes , poorly control type 2 diabetes Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>High cholesterol , Treatment high cholesterol , Lowering cholesterol , Lowering high cholesterol , Hypercholesterolemia</keyword>
</DOC>